The historical rank and industry rank for Glenmark Pharmaceuticals's FCF Margin % or its related term are showing as below:
NSE:GLENMARK'
s FCF Margin % Range Over the Past 10 Years
Min: -12.01 Med: 1.76 Max: 12.49
Current: 12.49
During the past 13 years, the highest FCF Margin % of Glenmark Pharmaceuticals was 12.49%. The lowest was -12.01%. And the median was 1.76%.
NSE:GLENMARK's FCF Margin % is ranked better than 76.05% of 956
companies
in the Drug Manufacturers industry
Industry Median: 2.48
vs NSE:GLENMARK: 12.49
Glenmark Pharmaceuticals FCF Margin % Related Terms
Glenmark Pharmaceuticals FCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GLENMARK vs ZTS, UTHR: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glenmark Pharmaceuticals FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Glenmark Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glenmark Pharmaceuticals (NSE:GLENMARK) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Glenmark Pharmaceuticals and its competitors. According to the industry distribution chart, Glenmark Pharmaceuticals ranks #229 out of 956 companies in the Drug Manufacturers industry, placing it in the top 24%.
Is Glenmark Pharmaceuticals' FCF Margin % too high?
Glenmark Pharmaceuticals' current FCF Margin % is 0.00%. Based on the distribution chart, Glenmark Pharmaceuticals ranks #229 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Glenmark Pharmaceuticals has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glenmark Pharmaceuticals' FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Glenmark Pharmaceuticals ranks #229 out of 956 companies for FCF Margin %. This places Glenmark Pharmaceuticals in the top 24% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.48, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Glenmark Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glenmark Pharmaceuticals's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glenmark Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals (NSE:GLENMARK) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,988.54, compared to a current price of ₹2,186.60 — trading 10% above its estimated fair value. The current FCF Margin % is 0.00%. Glenmark Pharmaceuticals' overall GF Score™ is 86/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Glenmark Pharmaceuticals (NSE:GLENMARK), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glenmark Pharmaceuticals (NSE:GLENMARK) Overvalued in 2026?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹2,186.60 is trading 10% above its estimated GF Value™ of ₹1,988.54.
GuruFocus considers Glenmark Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:GLENMARK:
FCF Margin %: 0.00%
GF Value™: ₹1,988.54 vs. price of ₹2,186.60 (10% above fair value)
No single metric tells the full story. See the NSE:GLENMARK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
86GF Score
Get the complete analysis for NSE:GLENMARK
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLENMARK has been successfully added to your 
